Among the conditions clinics treat with stem cells, liver disease has one of the more encouraging evidence bases — including randomized trials showing improved liver function and survival. It's still not a cure or a substitute for transplant, but for patients with cirrhosis, it's worth understanding clearly.
Cirrhosis and why it's hard to treat
Cirrhosis is advanced scarring (fibrosis) of the liver from chronic injury — hepatitis B or C, alcohol, or fatty liver disease. As scar tissue replaces working liver, function declines, and in decompensated cirrhosis, complications mount. Options have traditionally been limited to managing complications and, for end-stage disease, transplant — which is constrained by donor availability.
Why stem cells may help
Mesenchymal stem cells secrete a cocktail of factors relevant to the liver — including hepatocyte growth factor (HGF) and VEGF — that can support liver-cell survival, modulate immune activity, and exert anti-fibrotic effects. Rather than "becoming" new liver, MSCs appear to work mainly by creating an environment that favors repair and reduces ongoing inflammation.
What the trials show
The evidence here is more substantial than for many regenerative applications:
- A systematic review and meta-analysis of 11 clinical trials found MSC infusion significantly increased albumin (a marker of liver synthetic function) and decreased MELD scores (a measure of disease severity) at multiple time points — with no severe adverse events reported.
- A long-term randomized controlled trial in patients with hepatitis-B-related decompensated cirrhosis — using three umbilical-cord MSC infusions — reported significantly higher overall survival and liver-cancer-free survival over a 75-month follow-up versus standard care alone.
What treatment involves
Protocols typically use umbilical-cord-derived MSCs delivered by intravenous infusion or, in some studies, via the hepatic artery — often as a series of infusions spaced weeks apart. Treatment is paired with standard liver care and monitoring of liver function over months.
Important limits
What this is — and isn't
The evidence is most relevant to viral and decompensated cirrhosis, and outcomes measured are improvements in liver function and survival — not reversal to a healthy liver. Stem cell therapy does not replace liver transplantation for end-stage disease, and results vary between studies. It's best understood as a potential way to support liver function and slow decline, alongside — not instead of — hepatology care.
In Colombia
Colombian clinics offer IV and, in some cases, arterial UC-MSC protocols for liver patients, at costs well below US pricing. Given the seriousness of cirrhosis, coordinate with a hepatologist and ensure any clinic provides proper pre-treatment assessment and follow-up monitoring of liver markers.
Who might consider it
Patients with cirrhosis — particularly viral or decompensated — who want to explore an evidence-supported adjunct to standard care, and who understand it's not a cure or a transplant alternative, are the most reasonable candidates. A current hepatology evaluation should come first.
Exploring stem cell options for liver disease?
We'll help you find clinics with proper assessment and monitoring protocols — and set realistic expectations. Free and pressure-free.
Get a Free Consultation